📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Principal results of a randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with a 12 h regimen of N-acetylcysteine for paracetamol overdose (POP trial). (2019)

First Author: Morrison EE

Attributed to: Confidence in Concept 2012 - Edinburgh funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.ebiom.2019.07.013

PubMed Identifier: 31311721

Publication URI: http://europepmc.org/abstract/MED/31311721

Type: Journal Article/Review

Volume: 46

Parent Publication: EBioMedicine

ISSN: 2352-3964